trending Market Intelligence /marketintelligence/en/news-insights/trending/BTK6gMtP7WoZFJsQQ3a_Mg2 content esgSubNav
In This List

Arena Pharmaceuticals heart failure drug APD418 gets fast-track tag from US FDA

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022

Blog

Insight Weekly: CEO pay jumps; yield curve inversion deepens; wind giants lift turbine prices


Arena Pharmaceuticals heart failure drug APD418 gets fast-track tag from US FDA

Arena Pharmaceuticals Inc.'s heart failure therapy APD418 received the U.S. Food and Drug Administration's fast-track designation.

The designation gives regulatory priority to treatments that show promise and offers incentives such as more frequent communication with the regulator and the opportunity to apply for accelerated approval and priority review.

San Diego-based Arena's therapy treats the sudden worsening of heart failure symptoms, referred to as decompensated heart failure. APD418 is being tested in an early-stage clinical trial.